- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03110588
Phase I Trial of PACE for Metastatic Prostate Cancer
Phase I Trial of Prednisone, Abiraterone, Cabazitaxel and Enzalutamide (PACE) for Metastatic Castration-resistant Prostate Cancer (mCRPC)
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Multiple agents have been shown to improve survival in patients with mCRPC by up to five months. The combination of prednisone, abiraterone, cabazitaxel and enzalutamide may be anticipated to be feasible therapy with minimal or no adverse drug interactions. This is a phase I trial to study the feasibility of the proposed therapy.
Patients will undergo a combination of oral daily drug intake at varying doses over a period of three weeks. Monitoring including blood collection for laboratory testing will be done on Day 1 of each three-week cycle with additional monitoring during the first cycle. Imaging and correlative studies will be done every 12 weeks. Therapy will continue until disease progression or severe toxicities.
Study Type
Phase
- Phase 1
Contacts and Locations
Study Locations
-
-
Alabama
-
Birmingham, Alabama, United States, 35294
- University of Alabama at Birmingham
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Age ≥18 years
- Histologically proven adenocarcinoma of the prostate with metastatic disease.
- Progressive disease following androgen deprivation therapy; Prostate Specific Antigen (PSA) progression defined as baseline increase followed by any PSA increase greater than or equal to 1 week apart.
- Most recent PSA ≥2 ng/ml
- Testosterone < 50 ng/dL
- Anti-androgen withdrawal of first generation AR inhibitors (bicalutamide, nilutamide) is required for 6 weeks if previous duration of stability on them was ≥3 months.
- ECOG performance status 0-1.
Adequate organ function as defined below:
ANC 1,500/µl; Hemoglobin 10 g/dL; Platelet count 100,000/µL; Creatinine clearance ≥45 ml/min; Potassium >3.5 mmol/L (or within institutional normal range) Bilirubin ≤ ULN (unless documented Gilbert's disease); SGOT (AST) 1.5 x ULN; SGPT (ALT) 1.5 x ULN
- Subject agrees to use a double barrier method of contraception during the course of study therapy and for at least 3 months after completion of therapy. A double barrier method involves the use of a condom in combination one of the following: sponge, diaphragm, cervical ring with spermicidal gel or foam. Subjects who have had a vasectomy ≥6 months prior to trial therapy and those with female sexual partners who are 55 years old and post-menopausal for 2 years or sterile (by tubectomy, hysterectomy, bilateral oophorectomy) need to agree to use at least a condom.
- Ability to sign a written informed consent form.
- Subject is willing to stop herbal supplements.
Exclusion Criteria:
- Prior docetaxel for castration-resistant disease (prior docetaxel for castration-sensitive disease is allowed but not required).
- Prior enzalutamide, abiraterone, cabazitaxel.
- History of severe hypersensitivity reaction (≥grade 3) to docetaxel.
- History of severe hypersensitivity reaction (≥grade 3) to polysorbate 80 containing drugs.
- Concomitant vaccination with yellow fever vaccine.
- Prior investigational androgen synthesis or androgen receptor antagonists.
- Prior hypersensitivity reaction to capsule components of enzalutamide including labrasol, butylated hydroxyanisole and butylated hydroxytoluene
- Other non-chemotherapeutic investigational agents within 14 days (prior chemotherapy needs a ≥4 week washout).
- Concurrent or planned treatment with strong inhibitors or strong inducers of cytochrome P450 3A4/5 (a one week wash-out period is necessary for patients who are already on these treatments).
- Prior isotope therapy with Strontium-89, Samarium or radium-223.
- Patients with a history of central nervous system metastases (brain, meninges, spinal cord).
- Imminent risk of pathologic fracture or cord compression.
- History of seizures, underlying brain injury with loss of consciousness, transient ischemic attack within 12 months, cerebrovascular accident, and brain arteriovenous malformations.
- Uncontrolled severe intercurrent illness or medical conditions including, but not limited to, ongoing or active infection, symptomatic congestive heart failure (New York Heart Association Class III and IV heart failure), unstable angina pectoris, uncontrolled diabetes mellitus, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements or concurrent medications that alter cardiac conduction.
- Patients with a "currently active" second malignancy other than non- melanoma skin or superficial urothelial cancers are not eligible. Patients are not considered to have a "currently active" malignancy if they have completed therapy and are now considered without evidence of disease for 3 years.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Non-Randomized
- Interventional Model: Sequential Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: PACE with Cabazitaxel @ 15 mg/m2
The drugs to be administered are: prednisone 5 mg orally twice daily, abiraterone 1000 mg orally once daily, enzalutamide 160 mg orally once daily, and cabazitaxel intravenous infusion at 15 mg/m2 every 3 weeks.
|
Prednisone, Abiraterone, and Enzalutamide are administered orally; Cabazitaxel is be administered intravenously @ 15 mg/m2.
|
Experimental: PACE with Cabazitaxel @ 20 mg/m2
The drugs to be administered are: prednisone 5 mg orally twice daily, abiraterone 1000 mg orally once daily, enzalutamide 160 mg orally once daily, and cabazitaxel intravenous infusion at 20 mg/m2 every 3 weeks.
|
Prednisone, Abiraterone, and Enzalutamide are administered orally; Cabazitaxel is be administered intravenously @ 20 mg/m2.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Maximum tolerated dose of PACE as first-line therapy
Time Frame: Baseline up to 2 years
|
The maximum tolerated dose is when 6 patients are treated at a dose level with less than two patients demonstrating dose limiting toxicities.
Dose limiting toxicities are defined as any grade greater than or equal to grade 3 non-hematologic toxicity (except greater than or equal to grade 2 neurotoxicity), or greater than or equal to grade 4 neutropenia or thrombocytopenia lasting longer than or equal to 7 days.
Toxicities will be assessed according to the NCI Common Terminology Criteria for Adverse Events version 4.03.
|
Baseline up to 2 years
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Prostate specific antigen (PSA)
Time Frame: Baseline up to 2 years
|
PSA with a greater than or equal to 30% result within 12 weeks from baseline or the previous result and maximum declines at any time during the study progression.
PSA will be tested at least every 3 weeks.
|
Baseline up to 2 years
|
Radiographic progression-free survival with PACE
Time Frame: Baseline up to 2 years
|
Radiographic examination is performed every 12 weeks to determine if there is disease progression.
|
Baseline up to 2 years
|
Progression-free survival with PACE
Time Frame: Baseline up to 2 years
|
Progression-free survival is defined as the duration of time from start of treatment to time of progression or death, whichever comes first.
|
Baseline up to 2 years
|
Objective response rate of measurable disease
Time Frame: Baseline up to 2 years
|
Response will be evaluated using the new international criteria proposed by the Response Evaluation Criteria in Solid Tumors (RECIST 1.1).
Changes in only the largest diameter (unidimensional measurement) of the tumor lesions are used in the RECIST criteria.
Target lesions should be selected based on size (lesions with the longest diameter) and their suitability for accurate repeated measurements.
A sum of the longest diameter (LD) for all target lesions will be calculated and reported as the baseline sum LD, which will be used to characterize the objective tumor response.
|
Baseline up to 2 years
|
Pain response
Time Frame: Baseline up to 2 years
|
The Patient Pain Index (0-5 scale) is used to measure pain per cycle.
A decline of greater than or equal to 2 is defined as pain response.
|
Baseline up to 2 years
|
Collaborators and Investigators
Investigators
- Principal Investigator: Mansoor N Saleh, MD, University of Alabama at Birmingham
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- F161215003 (UAB 1663)
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Metastatic Prostate Cancer
-
Imperial College LondonWellcome Trust; Imperial Clinical Trials Unit (ICTU)CompletedProstate Cancer | Metastatic Prostate Cancer | Prostate Adenocarcinoma | Prostate Cancer Metastatic | Metastatic Prostate Carcinoma in the Soft Tissue | Non-metastatic Prostate CancerUnited Kingdom
-
The University of Texas Health Science Center at...WithdrawnMetastatic Prostate Cancer | Prostate Cancer Metastatic | Metastatic Prostate Adenocarcinoma | Castrate Resistant Prostate CancerUnited States
-
Dana MathewsWithdrawnProstate Cancer | Prostate Cancer Metastatic | Prostate Cancer Metastatic to BoneUnited States
-
Herlev and Gentofte HospitalBristol-Myers SquibbRecruitingProstate Cancer Metastatic | Metastatic Castration-resistant Prostate Cancer | Castrate Resistant Prostate Cancer | Prostate Cancer Stage IVDenmark
-
Myovant Sciences GmbHRecruitingMetastatic Castration-Resistant Prostate Cancer | Metastatic Castration-Sensitive Prostate Cancer | Non-Metastatic Castration-Resistant Prostate CancerUnited States
-
Bellicum PharmaceuticalsSuspendedMetastatic Prostate Cancer | Metastatic Castration-resistant Prostate CancerUnited States
-
Dana-Farber Cancer InstituteEpizyme, Inc.; PfizerRecruitingMetastatic Prostate Cancer | Metastatic Castration-resistant Prostate CancerUnited States
-
Tavanta TherapeuticsCompletedMetastatic Prostate Cancer | Metastatic Castration-sensitive Prostate Cancer | Metastatic Castration-resistant Prostate CancerUnited States, Spain, United Kingdom, Hungary, France, Poland, Puerto Rico, Sweden
-
Memorial Sloan Kettering Cancer CenterProgenics Pharmaceuticals, Inc.RecruitingProstate Cancer | Metastatic Prostate Cancer | Prostate Adenocarcinoma | Prostate Cancer Metastatic | Prostate NeoplasmUnited States
-
Vadim S KoshkinEli Lilly and Company; Prostate Cancer FoundationActive, not recruitingCastration-Resistant Prostate Carcinoma | Stage IV Prostate Cancer AJCC v8 | Stage IVA Prostate Cancer AJCC v8 | Stage IVB Prostate Cancer AJCC v8 | Metastatic Castration-resistant Prostate Cancer | Metastatic Prostate Adenocarcinoma | Metastatic Castration-resistant Prostate CarcinomaUnited States
Clinical Trials on PACE with Cabazitaxel (15 mg/m2)
-
Spanish Oncology Genito-Urinary GroupCompleted
-
Fundacion OncosurCompleted
-
Xian-Janssen Pharmaceutical Ltd.CompletedMyelodysplastic SyndromeChina
-
Janssen Pharmaceutical K.K.CompletedMyelodysplastic SyndromeJapan
-
Bay Area Gynecology OncologyUnknownCervical Cancer | Ovarian Cancer | Fallopian Tube Cancer | Peritoneal Cancer | Uterine Cancer | Gastrointestinal Cancers | MesotheliomasUnited States
-
Spectrum Health HospitalsCompletedMultiple MyelomaUnited States
-
William Sikov MDThe Miriam Hospital; Rhode Island Hospital; Memorial Hospital of Rhode IslandCompletedRectal Cancer | Colon CancerUnited States
-
Cancer Institute and Hospital, Chinese Academy...Jiangsu HengRui Medicine Co., Ltd.Unknown
-
University Hospital FreiburgCompletedAcute Myeloid LeukemiaGermany, Netherlands
-
University Hospital, GrenobleTerminatedKidney Transplantation | End-stage Renal Disease | Hla-incompatible Kidney Transplant CandidatesFrance